What is Wedbush's Forecast for BCRX FY2025 Earnings?

Key Points

• Wedbush has raised its FY2025 earnings estimate for BioCryst Pharmaceuticals to $0.14 per share, up from $0.13, and maintains an "Outperform" rating with an $18.00 price target.
• BioCryst Pharmaceuticals recently reported earnings of $0.15 per share for the last quarter, significantly exceeding analysts' expectations of $0.03, alongside a 49.5% year-over-year revenue increase to $163.35 million.
• Institutional investors own 85.88% of BioCryst Pharmaceuticals' stock, indicating strong support from larger investment firms.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at Wedbush raised their FY2025 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report issued on Monday, August 4th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $0.14 per share for the year, up from their previous estimate of $0.13. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2029 earnings at $1.04 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period in the previous year, the company earned ($0.06) earnings per share. The business's revenue for the quarter was up 49.5% on a year-over-year basis.

Several other analysts also recently weighed in on BCRX. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. JPMorgan Chase & Co. raised their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.19 during mid-day trading on Thursday, reaching $8.12. 1,146,039 shares of the company traded hands, compared to its average volume of 3,872,148. The stock has a market cap of $1.70 billion, a PE ratio of -45.09, a price-to-earnings-growth ratio of 1.89 and a beta of 1.10. The company's fifty day moving average is $9.32 and its two-hundred day moving average is $8.77. BioCryst Pharmaceuticals has a fifty-two week low of $6.01 and a fifty-two week high of $11.31.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BCRX. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in BioCryst Pharmaceuticals by 7.7% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock worth $161,000 after acquiring an additional 1,288 shares during the period. ANB Bank bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $172,000. Rockefeller Capital Management L.P. bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $229,000. Creative Planning lifted its position in shares of BioCryst Pharmaceuticals by 11.3% during the 2nd quarter. Creative Planning now owns 86,197 shares of the biotechnology company's stock worth $772,000 after buying an additional 8,748 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of BioCryst Pharmaceuticals by 441.5% in the 2nd quarter. SG Americas Securities LLC now owns 235,532 shares of the biotechnology company's stock worth $2,110,000 after purchasing an additional 192,036 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.